Business
Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate
- Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of
About this update from Avalon Globocare Corp.
[{"type":"text","content":"- Avalon forms strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria and the nanotechnology laboratory of Professor Uwe B. Sleytr on a novel S-layer SARS-CoV-2 (COVID-19) vaccine\n - Avalon and BOKU have already begun to develop a novel SARS-CoV-2 vaccine that can be administered by an intranasal or oral route - Avalon and Professor Sleytr of BOKU have jointly filed a USPTO provisional patent application on a novel design and implementation of S-layer structure technology for vaccine development FREEHOLD, N.J., June 25, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, announced today a strategic partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria to develop an S-layer vaccine that can be administered by an intranasal or oral route against SARS-CoV-2, the novel coronavirus that causes COVID-19 disease. The principal investigator of the co-development project is BOKU’s Professor Uwe B. Sleytr, an eminent member of the Austrian Academy of Sciences. Professor Sleytr is a pioneer of applied surface layer (“S-layer”) nanotechnology, based on the repetitive protein structures that make up the outer surface of microbial cells. Dr. Eva-Kathrin Ehmoser, Professor and Head of the Institute for Synthetic Bioarchitectures at BOKU, serves as the co-principal investigator of the COVID-19 vaccine program. Given the continued rise of COVID-19 cases around the world, Avalon and the BOKU scientists are working closely to co-develop a novel SARS-CoV-2 vaccine that would induce a sufficient immune response to prevent a severe form of COVID-19, which causes morbidity and often mortality. This vaccine strategy has the dual advantages of ease of manufacturing and delivery. The candidate vaccine is derived from a fusion of an S-layer viral particle mimic with the SARS-CoV-2 spike protein and could be delivered non-invasively via the nasal or oral passageways, rather than a needle-based injection into the muscle or under the skin. The S-layer protein-based vaccine is expected to both decrease the severity of a SARS-CoV-2 infection—preventing the more severe respiratory inflammation and organ damage seen in many COVID-19 patients—and build imm...